2010 - Concurrent PPIs and antibiotics for incident C. difficile infection were associated with increased risk for recurrent infection
- No link between nosocomial C. difficile recurrence, concurrent PPI use/infection treatment. // Infectious Disease News;Nov2013, Vol. 26 Issue 11, p36
The article discusses research being done on the use of proton pump inhibitors in patients with Clostridium difficile infection, which references a study by Daniel E. Freeberg and colleagues published in a 2013 issue of the "American Journal of Gastroenterology."
- PPI/antibiotic interaction increases CDI risk. // Reactions Weekly;8/27/2011, Issue 1366, p4
The article discusses research study done by V. Stevens and colleagues on the differential risk of clostridium difficile infection with proton pump inhibitor used by level of antibiotic exposure, published online in the August 10, 2011 issue of "Pharmacoepidemiology and Drug Safety."
- Proton pump inhibitors increase risk of C. difficile infection. // Reactions Weekly;5/26/2012, Issue 1403, p2
The article discusses research done C. S. Kwok and colleagues on the association between proton pump inhibitor (PPI) therapy and an increased risk of incident and recurrent Clostridium difficile infection, published in the April 24, 2012 issue of the "American Journal of Gastroenterology."
- Proton Pump Inhibitors and Clostridium Difficile Infection: Are We Propagating an Already Rapidly Growing Healthcare Problem? Patil, Rashmee; Blankenship, LeAnn // Gastroenterology Research;Oct2013, Vol. 6 Issue 5, p171
Proton pump inhibitors (PPIs) have been associated with Clostridium difficile infection (CDI) in several recent studies. The exact mechanism through which PPIs may cause Clostridium difficile infection is not well understood. One potential mechanism to explain this association may be that...
- Helicobacter pylori Treatment: A Practical Approach. Vakil, Nimish // American Journal of Gastroenterology;Mar2006, Vol. 101 Issue 3, p497
The treatment of Helicobacter pylori infection has become complicated by the lack of new treatment regimens and the emergence of drug resistant strains of H. pylori. Metronidazole and clarithromycin resistance are common in developed countries. Eradication rates have been falling in trials and...
- Review: 7-day proton-pump inhibitor-based triple therapy is as effective as > 7 days of the same regimen for heading H. pylori--associated peptic ulcer. Zanten, Sunder Veldhuyzen van // ACP Journal Club;Sep/Oct2005, Vol. 143 Issue 2, p49
The article presents a study that compares the efficacy of 7-day proton-pump inhibitor-based triple therapy regimen with regimen of more than seven days of the same regimen for healing the peptic ulcer. Researchers analyzed controlled trials in any language except Japanese that endoscopically...
- PPIs, Clostridium difficile, and Bone Fractures. Elliott, William T. // Clinical Oncology Alert;Jul2010 Supplement, p1
The article presents studies about the infections that may be caused by using chronic proton pump inhibitor (PPI) published in the May 10, 2010 issue of "Archives of Internal Medicine." In one study, the researchers examined more than 101,796 discharges from a tertiary care medical center and...
- Optimising gut colonisation resistance against Clostridium difficile infection. Yuille, S.; Mackay, W.; Morrison, D.; Tedford, M. // European Journal of Clinical Microbiology & Infectious Diseases;Nov2015, Vol. 34 Issue 11, p2161
Clostridium difficile is the dominant cause of pseudomembranous colitis in nosocomial environments. C. difficile infection (CDI) generally affects elderly (â‰¥65 years of age) hospital inpatients who have received broad-spectrum antimicrobial treatment. CDI has a 30 % risk of re-infection...
- New molecular mechanisms of resistance of Helicobacter pylori to clarithromycin. Pietroiusti, A.; Fontana, C.; Minelli, S.; Favalli, C.; Magrini, A.; Favaro, M.; Bergamaschi, A.; Iannaccone, U.; Galante, A. // Gut;Sep2002 Supplement 2, Vol. 51, pA3
Currently used therapies for Helicobacter pylori eradication include two antimicrobial (clarithromycin plus amoxicillin or metronidazole) plus a proton pump inhibitor. Although H. pylori is susceptible to most antimicrobial agents in vitro, in vivo eradication may difficult (12). The increased...